The DOI matches its Crossref record; 125 of the 125 references it cites were found in a registry or an index.
Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs
Open accessAbstract
Use of highly pure antigens to improve vaccine safety has led to reduced vaccine immunogenicity and efficacy. This has led to the need to use adjuvants to improve vaccine immunogenicity. The ideal adjuvant should maximize vaccine immunogenicity without compromising tolerability or safety. Unfortunately, adjuvant research has lagged behind other vaccine areas such as antigen discovery, with the consequence that only a very limited number of adjuvants based on aluminium salts, monophosphoryl lipid A and oil emulsions are currently approved for human use. Recent strategic initiatives to support adjuvant development by the National Institutes of Health should translate into greater adjuvant choices in the future. Mechanistic studies have been valuable for better understanding of adjuvant action, but mechanisms of adjuvant toxicity are less well understood. The inflammatory or danger-signal model of adjuvant action implies that increased vaccine reactogenicity is the inevitable price for improved immunogenicity. Hence, adjuvant reactogenicity may be avoidable only if it is possible to separate inflammation from adjuvant action. The biggest remaining challenge in the adjuvant field is to decipher the potential relationship between adjuvants and rare vaccine adverse reactions, such as narcolepsy, macrophagic myofasciitis or Alzheimer’s disease. While existing adjuvants based on aluminium salts have a strong safety record, there are ongoing needs for new adjuvants and more intensive research into adjuvants and their effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hoffman, H. M., Mueller, J. L., Broide, D. H., Wanderer, A. A., & Kolodner, R. D. (2001) · Nature Genetics · doi:10.1038/ng756 · Cited by 1,682
Klinman, D. M., Yi, A. K., Beaucage, S. L., Conover, J., & Krieg, A. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.7.2879 · Cited by 1,477
Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073623.84147.a8 · Cited by 1,356
Therapeutic potential of Toll-like receptor 9 activation
Krieg, A. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2059 · Cited by 1,246
Sutton, C., Brereton, C., Keogh, B., Mills, K. H. G., & Lavelle, E. C. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060285 · Cited by 1,010
Vaccine adjuvants: Current state and future trends
Petrovsky, N., & Aguilar, J. C. (2004) · Immunology & Cell Biology · doi:10.1111/j.0818-9641.2004.01272.x · Cited by 1,005
Self-citationDidierlaurent, A. M., Morel, S., Lockman, L., Giannini, S. L., Bisteau, M., Carlsen, H., Kielland, A., Vosters, O., Vanderheyde, N., Schiavetti, F., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901474 · Cited by 758
Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses
Morein, B., Sundquist, B., Höglund, S., Dalsgaard, K., & Osterhaus, A. (1984) · Nature · doi:10.1038/308457a0 · Cited by 708
Aluminum compounds as vaccine adjuvants
Gupta, R. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00008-8 · Cited by 623
Hartmann, G., Weeratna, R. D., Ballas, Z. K., Payette, P., Blackwell, S., Suparto, I., Rasmussen, W. L., Waldschmidt, M., Sajuthi, D., Purcell, R. H., et al. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.3.1617 · Cited by 585
Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice.
Agrawal, S., Temsamani, J., & Tang, J. Y. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.17.7595 · Cited by 561
Treating inflammation by blocking interleukin-1 in humans
Dinarello, C. A., & van der Meer, J. W. M. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.10.008 · Cited by 549
Critical contribution of liver natural killer T cells to a murine model of hepatitis
Takeda, K., Hayakawa, Y., Van Kaer, L., Matsuda, H., Yagita, H., & Okumura, K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.040566697 · Cited by 539
Nohynek, H., Jokinen, J., Partinen, M., Vaarala, O., Kirjavainen, T., Sundman, J., Himanen, S.-L., Hublin, C., Julkunen, I., Olsén, P., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033536 · Cited by 498
Heikenwalder, M., Polymenidou, M., Junt, T., Sigurdson, C., Wagner, H., Akira, S., Zinkernagel, R., & Aguzzi, A. (2004) · Nature Medicine · doi:10.1038/nm987 · Cited by 449 · cited 1×
“However, the phosphorothioate backbone has been shown to cause increased adverse effects in murine models, including splenomegaly, lymphoid follicle destruction and immunosuppression [103, 105].”
BackgroundDavis, I. D., Chen, W., Jackson, H., Parente, P., Shackleton, M., Hopkins, W., Chen, Q., Dimopoulos, N., Luke, T., Murphy, R., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403572101 · Cited by 440
Stils, H. F. (2005) · ILAR Journal · doi:10.1093/ilar.46.3.280 · Cited by 434
Willhite, C. C., Karyakina, N. A., Yokel, R. A., Yenugadhati, N., Wisniewski, T. M., Arnold, I. M. F., Momoli, F., & Krewski, D. (2014) · Critical Reviews in Toxicology · doi:10.3109/10408444.2014.934439 · Cited by 412
Partinen, M., Saarenpää-Heikkilä, O., Ilveskoski, I., Hublin, C., Linna, M., Olsén, P., Nokelainen, P., Alén, R., Wallden, T., Espo, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033723 · Cited by 406
Flagellin as an Adjuvant: Cellular Mechanisms and Potential
Mizel, S. B., & Bates, J. T. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1002156 · Cited by 399 · cited 1×
“A further TLR-based adjuvant approach that has been tested in preliminary human trials is the TLR5 ligand flagellin [113].”
BackgroundAluminium adjuvants—in retrospect and prospect
Lindblad, E. B. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.03.032 · Cited by 362
Gherardi, R. K. (2001) · Brain · doi:10.1093/brain/124.9.1821 · Cited by 361
Influenza and the challenge for immunology
Doherty, P. C., Turner, S. J., Webby, R. G., & Thomas, P. G. (2006) · Nature Immunology · doi:10.1038/ni1343 · Cited by 356
COOPER, C. L., DAVIS, H. L., MORRIS, M. L., EFLER, S. M., ADHAMI, M. A., KRIEG, A. M., CAMERON, D. W., & HEATHCOTE, J. (2004) · Journal of Clinical Immunology · doi:10.1007/s10875-004-6244-3 · Cited by 330
Cholera toxin and cholera B subunit as oral—mucosal adjuvant and antigen vector systems
Holmgren, J., Lycke, N., & Czerkinsky, C. (1993) · Vaccine · doi:10.1016/0264-410x(93)90039-z · Cited by 325
Scheiermann, J., & Klinman, D. M. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.06.065 · Cited by 322
Schroder, K., Irvine, K. M., Taylor, M. S., Bokil, N. J., Le Cao, K.-A., Masterman, K.-A., Labzin, L. I., Semple, C. A., Kapetanovic, R., Fairbairn, L., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110156109 · Cited by 308
CpG motifs as immune adjuvants
Klinman, D. M., Barnhart, K. M., & Conover, J. (1999) · Vaccine · doi:10.1016/s0264-410x(98)00151-0 · Cited by 308
Lewis, D. J. M., Huo, Z., Barnett, S., Kromann, I., Giemza, R., Galiza, E., Woodrow, M., Thierry-Carstensen, B., Andersen, P., Novicki, D., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006999 · Cited by 305
Turley, C. B., Rupp, R. E., Johnson, C., Taylor, D. N., Wolfson, J., Tussey, L., Kavita, U., Stanberry, L., & Shaw, A. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.05.041 · Cited by 294
TLR9 Signaling in B Cells Determines Class Switch Recombination to IgG2a
Jegerlehner, A., Maurer, P., Bessa, J., Hinton, H. J., Kopf, M., & Bachmann, M. F. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.4.2415 · Cited by 273
Lorent, J. H., Quetin-Leclercq, J., & Mingeot-Leclercq, M.-P. (2014) · Org. Biomol. Chem. · doi:10.1039/c4ob01652a · Cited by 273
Shaw, C. A., & Tomljenovic, L. (2013) · Immunologic Research · doi:10.1007/s12026-013-8403-1 · Cited by 269
Freytag, L. C., & Clements, J. D. (2005) · Vaccine · doi:10.1016/j.vaccine.2004.11.010 · Cited by 252
van Dissel, J. T., Joosten, S. A., Hoff, S. T., Soonawala, D., Prins, C., Hokey, D. A., O’Dee, D. M., Graves, A., Thierry-Carstensen, B., Andreasen, L. V., et al. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.10.036 · Cited by 243
Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine
Wu, J. Y., Gardner, B. H., Murphy, C. I., Seals, J. R., Kensil, C. R., Recchia, J., Beltz, G. A., Newman, G. W., & Newman, M. J. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.148.5.1519 · Cited by 240
Alving, C. R., Peachman, K. K., Rao, M., & Reed, S. G. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.03.008 · Cited by 225
Chiew Tong, N. K., Beran, J., Kee, S. A., Miguel, J. L., SanNchez, C., Bayas, J. M., Vilella, A., De Juanes, J. R., Arrazola, P., Calbo-Torrecillas, F., et al. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00689.x · Cited by 219
Adjuvants: current status, clinical perspectives and future prospects
Audibert, F. M., & Lise, L. D. (1993) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(93)90204-w · Cited by 214
Honda-Okubo, Y., Barnard, D., Ong, C. H., Peng, B.-H., Tseng, C.-T. K., & Petrovsky, N. (2015) · Journal of Virology · doi:10.1128/jvi.02980-14 · Cited by 210
Self-citationAdjuvants: current status, clinical perspectives and future prospects
Audibert, F. M., & Lise, L. D. (1993) · Immunology Today · doi:10.1016/0167-5699(93)90046-n · Cited by 194
The mode of action of mineral-oil emulsion adjuvants on antibody production in mice.
Herbert, W. J. (1968) · PubMed · Cited by 193
Krieg, A. M., Efler, S. M., Wittpoth, M., Al Adhami, M. J., & Davis, H. L. (2004) · Journal of Immunotherapy · doi:10.1097/00002371-200411000-00006 · Cited by 184
Immunopathogenesis of vaccine-enhanced RSV disease
Openshaw, P. J. M., Culley, F. J., & Olszewska, W. (2001) · Vaccine · doi:10.1016/s0264-410x(01)00301-2 · Cited by 172
Honda-Okubo, Y., Saade, F., & Petrovsky, N. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.06.021 · Cited by 169
Self-citationGlanz, J. M., McClure, D. L., Magid, D. J., Daley, M. F., France, E. K., Salmon, D. A., & Hambidge, S. J. (2009) · Pediatrics · doi:10.1542/peds.2008-2150 · Cited by 167
Role of lysosome rupture in controlling Nlrp3 signaling and necrotic cell death
Lima Jr., H., Jacobson, L., Goldberg, M., Chandran, K., Diaz-Griffero, F., Lisanti, M. P., & Brojatsch, J. (2013) · Cell Cycle · doi:10.4161/cc.24903 · Cited by 162
Carbohydrate-based immune adjuvants
Petrovsky, N., & Cooper, P. D. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.30 · Cited by 157
Self-citationCentral nervous system disease in patients with macrophagic myofasciitis
Authier, F., Cherin, P., Creange, A., Bonnotte, B., Ferrer, X., Abdelmoumni, A., Ranoux, D., Pelletier, J., Figarella-Branger, D., Granel, B., et al. (2001) · Brain · doi:10.1093/brain/124.5.974 · Cited by 154
QS-21: a water-soluble triterpene glycoside adjuvant
Kensil, C. R., & Kammer, R. B. (1998) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.7.9.1475 · Cited by 152
Gavillet, B. M., Eberhardt, C. S., Auderset, F., Castellino, F., Seubert, A., Tregoning, J. S., Lambert, P., Gregorio, E. D., Giudice, G. D., & Siegrist, C. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402071 · Cited by 150
Treanor, J. J., Taylor, D. N., Tussey, L., Hay, C. M., Nolan, C., Fitzgerald, T. F., Liu, G., Kavita, U., Song, L., Dark, I., et al. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.10.009 · Cited by 148
Ahmed, S., Schur, P. H., MacDonald, N. E., & Steinman, L. (2014) · Journal of Autoimmunity · doi:10.1016/j.jaut.2014.01.033 · Cited by 145
Marson, A., Housley, W. J., & Hafler, D. A. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78086 · Cited by 140
Halperin, S. A., Ward, B. J., Cooper, C., Predy, G., Díaz‐Mitoma, F., Dionne, M., Embreé, J., McGeer, A., Zickler, P., Moltz, K.-H., et al. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.01.087 · Cited by 136
Goto, N., Kato, H., Maeyama, J., Shibano, M., Saito, T., Yamaguchi, J., & Yoshihara, S. (1997) · Vaccine · doi:10.1016/s0264-410x(97)00054-6 · Cited by 136
Lastra, O. L. V., Medina, G., Cruz-Domínguez, M. P., Jara, L. J., & Shoenfeld, Y. (2013) · Expert Review of Clinical Immunology · doi:10.1586/eci.13.2 · Cited by 136
Verdier, F., Burnett, R., Michelet, C., Moretto, P., Fievet-Groyne, F., & Sauzeat, E. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.09.012 · Cited by 135
Halperin, S. A., Dobson, S., McNeil, S., Langley, J. M., Smith, B. R., McCall-Sani, R., Levitt, D., Nest, G. V., Gennevois, D., & Eiden, J. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.08.095 · Cited by 134
Waite, D. C., Jacobson, E. W., Ennis, F. A., Edelman, R., White, B., Kammer, R. B., Anderson, C., & Kensil, C. R. (2001) · Vaccine · doi:10.1016/s0264-410x(01)00142-6 · Cited by 133
Cooper, P. D., & Petrovsky, N. (2010) · Glycobiology · doi:10.1093/glycob/cwq201 · Cited by 133
Self-citationNovel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants
Aimanianda, V., Haensler, J., Lacroix‐Desmazes, S., Kaveri, S. V., & Bayry, J. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.03.005 · Cited by 133
de Swart, R. L., Kuiken, T., Timmerman, H. H., van Amerongen, G., van den Hoogen, B. G., Vos, H. W., Neijens, H. J., Andeweg, A. C., & Osterhaus, A. D. M. E. (2002) · Journal of Virology · doi:10.1128/jvi.76.22.11561-11569.2002 · Cited by 133
Aluminum and Alzheimer's disease: A new look
Miu, A. C., & Bengà, O. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-102-306 · Cited by 127
Th17 and Non-Classic Th1 Cells in Chronic Inflammatory Disorders: Two Sides of the Same Coin
Cosmi, L., Liotta, F., Maggi, E., Romagnani, S., & Annunziato, F. (2014) · International Archives of Allergy and Immunology · doi:10.1159/000363502 · Cited by 124
McCarthy, J. S., Marjason, J. K., Elliott, S. L., Fahey, P., Bang, G., Malkin, E. M., Tierney, E. L., Aked-Hurditch, H., Adda, C. G., Cross, N., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024413 · Cited by 123
Heyward, W. L., Kyle, M., Blumenau, J., Davis, M., Reisinger, K. S., Kabongo, M. L., Bennett, S. R., Janssen, R. S., Namini, H., & Martin, J. T. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.05.068 · Cited by 121
Polyionic vaccine adjuvants: another look at aluminum salts and polyelectrolytes
Powell, B. S., Andrianov, A. K., & Fusco, P. C. (2015) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2015.4.1.23 · Cited by 117
Gordon, D., Sajkov, D., Woodman, R. J., Honda‐Okubo, Y., Cox, M. M. J., Heinzel, S., & Petrovsky, N. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.06.009 · Cited by 110
Self-citationPusic, K. M., Aguilar, Z. P., McLoughlin, J., Kobuch, S., Xu, H. T., Tsang, M., Wang, A., & Hui, G. S. N. (2012) · The FASEB Journal · doi:10.1096/fj.12-218362 · Cited by 103
Lin, Y., Epstein, D. L., & Liton, P. B. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-5410 · Cited by 102
Vaarala, O., Vuorela, A., Partinen, M., Baumann, M., Freitag, T. L., Meri, S., Saavalainen, P., Jauhiainen, M., Soliymani, R., Kirjavainen, T., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114361 · Cited by 97
Folb, P. I., Bernatowska, E. A., Chen, R. E., Clemens, J. D., Dodoo, A. N. O., Ellenberg, S. S., Farrington, P., John, T., Lambert, P., MacDonald, N. E., et al. (2004) · American Journal of Public Health · doi:10.2105/ajph.94.11.1926 · Cited by 97
Lobigs, M., Pavy, M., Hall, R. A., Lobigs, P., Cooper, P. D., Komiya, T., Toriniwa, H., & Petrovsky, N. (2010) · Journal of General Virology · doi:10.1099/vir.0.019190-0 · Cited by 97
Self-citationButler, N. R., Voyce, M. A., Burland, W. L., & Hilton, M. L. (1969) · BMJ · doi:10.1136/bmj.1.5645.663 · Cited by 96
Gordon, D., Kelley, P., Heinzel, S., Cooper, P. D., & Petrovsky, N. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.09.034 · Cited by 94
Self-citationAsuni, A. A., Boutajangout, A., Scholtzova, H., Knudsen, E., Li, Y. S., Quartermain, D., Frangione, B., Wısnıewskı, T., & Sigurdsson, E. M. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05149.x · Cited by 93
Tsai, T. F., Crucitti, A., Nacci, P., Nicolay, U., Cioppa, G. D., Ferguson, J., & Clemens, R. L. (2011) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365548.2011.580777 · Cited by 93
Aluminium in Allergies and Allergen immunotherapy
Jensen‐Jarolim, E. (2015) · World Allergy Organization Journal · doi:10.1186/s40413-015-0060-5 · Cited by 93
Intranasal Vaccination Promotes Detrimental Th17-Mediated Immunity against Influenza Infection
Maroof, A., Yorgensen, Y. M., Li, Y., & Evans, J. T. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1003875 · Cited by 91
Human adjuvant disease induced by foreign substances: a new model of ASIA (Shoenfeld's syndrome)
Lastra, O. L. V., Medina, G., Cruz-Domínguez, M. P., Ramirez, P., Gayosso-Rivera, J., Anduaga-Domínguez, H., Lievana-Torres, C., & Jara, L. J. (2012) · Lupus · doi:10.1177/0961203311429317 · Cited by 89
Larena, M., Holmgren, J. R., Lebens, M., Terrinoni, M., & Lundgren, A. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401633 · Cited by 83
Petrovsky, N., Larena, M., Siddharthan, V., Prow, N. A., Hall, R. A., Lobigs, M., & Morrey, J. D. (2013) · Journal of Virology · doi:10.1128/jvi.00480-13 · Cited by 81
Self-citationAluminum inclusion macrophagic myofasciitis: a recently identified condition
Gherardi, R. K., & Authier, F. (2003) · Immunology and Allergy Clinics of North America · doi:10.1016/s0889-8561(03)00095-x · Cited by 80
Toll-like receptor signalling and the clinical benefits that lie within
Verstak, B., Hertzog, P. J., & Mansell, A. S. (2007) · Inflammation Research · doi:10.1007/s00011-007-6093-7 · Cited by 79
Krug, A., Rothenfußer, S., Selinger, S., Bock, C., Kerkmann, M., Battiany, J., Sarris, A., Giese, T., Speiser, D. E., Endres, S., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.7.3468 · Cited by 74
Shaw, C., Li, Y., & Tomljenovic, L. (2013) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2013.07.022 · Cited by 72
Sablan, B. P., Kim, D. J., Barzaga, N. G., Chow, W. C., Cho, M., Ahn, S. H., Hwang, S. G., Lee, J.-H., Namini, H., & Heyward, W. L. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.02.001 · Cited by 68
Eidi, H., David, M.-O., Crépeaux, G., Henry, L., Joshi, V., Berger, M., Sennour, M., Cadusseau, J., Gherardi, R. K., & Curmi, P. A. (2015) · BMC Medicine · doi:10.1186/s12916-015-0388-2 · Cited by 66
Aluminium in allergen-specific subcutaneous immunotherapy – A German perspective
Kramer, M. F., & Heath, M. D. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.05.063 · Cited by 64
Vitoriano-Souza, J., Moreira, N. D. D., Teixeira‐Carvalho, A., Carneiro, C. M., Mathias, F. A. S., Vieira, P. M. D. A., Giunchetti, R. C., de Moura, S. A. L., Fujiwara, R. T., Melo, M. N., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040745 · Cited by 63
Use of human MonoMac6 cells for development of in vitro assay predictive of adjuvant safety in vivo
Zaitseva, M. B., Romantseva, T., Blinova, K., Beren, J. J., Sirota, L. A., Drane, D. P., & Golding, H. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.05.002 · Cited by 60
Fanni, D., Ambu, R., Gerosa, C., Nemolato, S., Iacovidou, N. M., Eyken, P. V., Fanos, V., Zaffanello, M., & Faa, G. (2014) · World Journal of Pediatrics · doi:10.1007/s12519-014-0477-x · Cited by 59
Bults, M., Beaujean, D., Richardus, J. H., van Steenbergen, J., & Voeten, H. A. C. M. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.06.075 · Cited by 58
Efficacy of ABX196, a new NKT agonist, in prophylactic human vaccination
Nitcheu-Tefit, J., Crabé, S., Orlandini, B., Nell, H., Bendelac, A. S., Deng, S., Savage, P. B., Teyton, L., & Serra, V. A. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.08.070 · Cited by 56
How society should respond to the risk of vaccine rejection
Ropeik, D. P. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.25250 · Cited by 55
Heat-Labile Enterotoxins as Adjuvants or Anti-Inflammatory Agents
Liang, S., & Hajishengallis, G. (2010) · Immunological Investigations · doi:10.3109/08820130903563998 · Cited by 54
Danger, diversity and priming in innate antiviral immunity
Collins, S. E., & Mossman, K. L. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.07.002 · Cited by 54
Feinen, B., Petrovsky, N., Verma, A., & Merkel, T. J. (2014) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00019-14 · Cited by 52
Self-citationInduction of recurrent experimental allergic encephalomyelitis with myelin basic protein
PANITCH, H. S., & Ciccone, C. (1981) · Annals of Neurology · doi:10.1002/ana.410090504 · Cited by 51
Clinical Features in Patients with Long-Lasting Macrophagic Myofasciitis
Rigolet, M., Aouizerate, J., Couette, M., Ragunathan-Thangarajah, N., Aoun-Sebaiti, M., Gherardi, R. K., Cadusseau, J., & Authier, F. J. (2014) · Frontiers in Neurology · doi:10.3389/fneur.2014.00230 · Cited by 51
Are there Negative CNS Impacts of Aluminum Adjuvants Used in Vaccines and Immunotherapy?
Shaw, C. A., Li, D., & Tomljenovic, L. (2014) · Immunotherapy · doi:10.2217/imt.14.81 · Cited by 50
Hypersensitivity Reactions to Vaccine Constituents: A Case Series and Review of the Literature
Leventhal, J. S., Berger, E. M., Brauer, J. A., & Cohen, D. E. (2012) · Dermatitis · doi:10.1097/der.0b013e31825228cf · Cited by 45
Predictive markers of safety and immunogenicity of adjuvanted vaccines
Mastelic, B., Garçon, N., Giudice, G. D., Golding, H., Gruber, M. F., Neels, P., & Fritzell, B. (2013) · Biologicals · doi:10.1016/j.biologicals.2013.08.006 · Cited by 44
Honda‐Okubo, Y., Kolpe, A. B., Li, L., & Petrovsky, N. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.06.057 · Cited by 41
Self-citationA global regulatory science agenda for vaccines
Elmgren, L., Li, X., Wilson, C. A., Ball, R., Wang, J., Cichutek, K., Pfleiderer, M., Kato, A., Cavaleri, M., Southern, J., et al. (2013) · Vaccine · doi:10.1016/j.vaccine.2012.10.117 · Cited by 38
Szebeni, J. (2005) · Current Drug Delivery · doi:10.2174/156720105774370212 · Cited by 38
Does Allergen-specific Immunotherapy Induce Contact Allergy to Aluminium?
Netterlid, E., Hindsén, M., Siemund, I., Björk, J., Werner, S., Jacobsson, H., Güner, N., & Bruze, M. (2013) · Acta Dermato Venereologica · doi:10.2340/00015555-1409 · Cited by 35 · cited 1×
“tact dermatitis to aluminium in a fraction of immunized subjects [33].”
BackgroundButtenheim, A. M., Cherng, S. T., & Asch, D. A. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.25635 · Cited by 34
Reusche, E., & Seydel, U. (1993) · Acta Neuropathologica · doi:10.1007/bf00304139 · Cited by 32
Antiphospholipid Antibody Syndrome: A Review
Bingley, P. J., & HOFFBRAND, B. I. (1987) · Journal of the Royal Society of Medicine · doi:10.1177/014107688708000716 · Cited by 31
Naik, S., & Wala, S. M. (2014) · Journal of Postgraduate Medicine · doi:10.4103/0022-3859.138799 · Cited by 31
CpG ODN mediated prevention from ovalbumin-induced anaphylaxis in mouse through B cell pathway
Xu, W. R., Tamura, T., & Takatsu, K. (2007) · International Immunopharmacology · doi:10.1016/j.intimp.2007.10.019 · Cited by 30
Glucosamine Dose/Concentration-Effect Correlation in the Rat with Adjuvant Arthritis
Aghazadeh‐Habashi, A., Kohan, H. G., Asghar, W., & Jamali, F. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23819 · Cited by 26
Nieuwenhuizen, N. E., Herbert, D. R., Lopata, A. L., & Brombacher, F. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.5.2758 · Cited by 25
Spadea, A., Unim, B., Colamesta, V., Meneghini, A., D'Amici, A. M., Giudiceandrea, B., & Torre, G. L. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.07.077 · Cited by 25
Viral immune surveillance: Toward a TH17/TH9 gate to the central nervous system
Barkhordarian, A., Thames, A. D., Du, A. M., Jan, A. L., Nahcivan, M., Nguyen, M. T., Sama, N., & Chiappelli, F. (2015) · Bioinformation · doi:10.6026/97320630011047 · Cited by 24
Zivkovic, I. P., Petrušić, V., Stojanović, M., Inić‐Kanada, A., Stojićević, I., & Dimitrijević, L. (2011) · Innate Immunity · doi:10.1177/1753425911407361 · Cited by 24
Consent and public engagement in an era of expanded childhood immunisation
Leask, J., Braunack‐Mayer, A., & Kerridge, I. (2011) · Journal of Paediatrics and Child Health · doi:10.1111/j.1440-1754.2011.02160.x · Cited by 23
Murine Experimental Autoimmune Hepatitis: Nonspecific Inflammation Due to Adjuvant Oil
Howell, C. D., & Yoder, T. D. (1994) · Clinical Immunology and Immunopathology · doi:10.1006/clin.1994.1109 · Cited by 21
A genomics-based approach to assessment of vaccine safety and immunogenicity in children
White, O. J., McKenna, K. L., Bosco, A., van den Biggelaar, A. H. J., Richmond, P., & Holt, P. G. (2012) · Vaccine · doi:10.1016/j.vaccine.2011.12.118 · Cited by 20
Immunotherapy – 2076. A controlled study of delta inulin-adjuvanted honey bee venom immunotherapy
Heddle, R. J., Russo, P., Petrovsky, N., Hanna, R., & Smith, A. (2013) · World Allergy Organization Journal · doi:10.1186/1939-4551-6-s1-p158 · Cited by 17
Self-citationRethinking vaccine policy making in an era of vaccine hesitancy: Time to rebuild, not remodel?
Opel, D. J., & Marcuse, E. K. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.26651 · Cited by 11
Bègué, P. (2010) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)32267-8 · Cited by 11
Li‐Kim‐Moy, J. P., & Booy, R. (2015) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12337 · Cited by 10
Cited by
International consensus statement on allergy and rhinology: Allergic rhinitis – 2023
Wise, S. K., Damask, C., Roland, L. T., Ebert, C., Levy, J. M., Lin, S., Luong, A., Rodriguez, K., Sedaghat, A. R., Toskala, E., et al. (2023) · International Forum of Allergy & Rhinology · doi:10.1002/alr.23090 · Cited by 507
Next-generation influenza vaccines: opportunities and challenges
Wei, C.-J., Crank, M. C., Shiver, J., Graham, B. S., Mascola, J. R., & Nabel, G. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0056-x · Cited by 332
Progress and Prospects on Vaccine Development against SARS-CoV-2
Zhang, J., Zeng, H., Gu, J., Li, H., Zheng, L., & Zou, Q. (2020) · Vaccines · doi:10.3390/vaccines8020153 · Cited by 282
An Overview of Novel Adjuvants Designed for Improving Vaccine Efficacy
Bonam, S. R., Partidos, C. D., Halmuthur, S. K. M., & Muller, S. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.06.002 · Cited by 261
Yoshida, S., Nakagami, H., Hayashi, H., Ikeda, Y., Sun, J., Tenma, A., Tomioka, H., Kawano, T., Shimamura, M., Morishita, R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16347-w · Cited by 161
Metadata
- Authors
- Petrovsky, N.
- Venue
- Drug Safety
- Published
- 2015-10-08
- Volume
- 38
- Issue
- 11
- Pages
- 1059-1074
- ISSN
- 0114-5916 (ISSN-L)
- 1179-1942
- OpenAlex
- W1895518456
- Cited by
- 366
- References
- 125
- FWCI
- 5.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.